Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis

Colomba, Netedu, Lehoux-Dubois, Coriati, Boudreau, Tremblay, Cusi, Rabasa-Lhoret, Leey (2019) Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis PLoS One (IF: 3.7) 14(7) e0219855
Full Text
Full text

Click the PDF icon to view the full text of the paper

Abstract

Cystic fibrosis (CF) patients are at high risk of developing CF-related diabetes (CFRD). In non-CF patients, liver disease, specifically steatosis and non-alcoholic fatty liver disease (NAFLD), is strongly associated with type 2 diabetes. We compared glycemic status and metabolic profiles in CF patients according to a biomarker of hepatic injury, alanine aminotransferase (ALT).We conducted a cross-sectional study among 273 adult CF patients recruited from the Montreal CF Cohort. A 2-hour oral glucose tolerance test (OGTT) was performed to collect glucose and insulin measures every 30 minutes. Fasting ALT levels and anthropometric measures were also obtained. Patients were categorized into 2 groups based on ALT cut-off of 25 U/L.Patients in the high ALT group were mostly men (83%), had higher mean weight and BMI (p<0.001) and showed elevated glucose levels throughout OGTT (p≤0.01). When stratified by sex, only men with high ALT showed significantly higher weight (p<0.001), higher glycemic values at 60, 90 and 120 minutes of OGTT (p≤0.01), higher frequency of de novo CFRD (20.5% vs 8.2%, p = 0.04) as well as lower insulin sensitivity than men with normal ALT (p = 0.03). ALT levels were strongly associated with HOMA-IR in CFRD patients (p = 0.001, r2 = 0.28).Adult CF men with higher ALT show an increased frequency of dysglycemia and de novo CFRD, lower insulin sensitivity and higher eight. Our data suggests that ALT levels could be an interesting tool to guide targeted diabetes screening, particularly among CF men. Prospective studies are needed to confirm these observations.

Links

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638946
http://www.ncbi.nlm.nih.gov/pubmed/31318914
http://dx.doi.org/10.1371/journal.pone.0219855

Similar articles

Tools